Tigran Makunts

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Topics

Advanced Non Small Cell Lung Cancer

Drug Administration

Renal Cell Carcinoma

Top Venues

medRxiv : the preprint server for health sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events. medRxiv : the preprint server for health sciences (2024)
Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events. medRxiv : the preprint server for health sciences (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events. medRxiv : the preprint server for health sciences (2024)
Tigran Makunts, Siranuysh Grabska, Hovakim Grabski, Ruben Abagyan
Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events. medRxiv : the preprint server for health sciences (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis. JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Authors' Response to Peer Reviews of "Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis". JMIRx med 5 (2024)
Tigran Makunts, Haroutyun Joulfayan, Ruben Abagyan
Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System. medRxiv : the preprint server for health sciences (2023)
Tigran Makunts, Keith Burkhart, Ruben Abagyan, Peter Lee
Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. PloS one 17 (2) (2022)